The stock of NLS Pharmaceutics Ltd (NLSP) has seen a 1.22% increase in the past week, with a 13.79% gain in the past month, and a -27.63% decrease in the past quarter. The volatility ratio for the week is 7.28%, and the volatility levels for the past 30 days are at 6.32% for NLSP. The simple moving average for the last 20 days is 3.28% for NLSP stock, with a simple moving average of -49.39% for the last 200 days.
Is It Worth Investing in NLS Pharmaceutics Ltd (NASDAQ: NLSP) Right Now?
The 36-month beta value for NLSP is also noteworthy at -0.09. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for NLSP is 1.57M, and at present, short sellers hold a 5.82% of that float. The average trading volume of NLSP on May 20, 2025 was 71.49K shares.
NLSP) stock’s latest price update
The stock price of NLS Pharmaceutics Ltd (NASDAQ: NLSP) has plunged by -3.51 when compared to previous closing price of 1.71, but the company has seen a 1.22% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-04-15 that Non-opioid, multi-mechanism profile positions Mazindol as a differentiated asset in addiction therapeutics Favorable results support potential expansion into high-value markets beyond ADHD and narcolepsy ZURICH, April 15, 2025 /PRNewswire/ — NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (NASDAQ: NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced positive results from Study KO-943, a preclinical investigation evaluating the efficacy of Mazindol in mitigating fentanyl-induced conditioned place preference (CPP) in mice.
NLSP Trading at 7.90% from the 50-Day Moving Average
After a stumble in the market that brought NLSP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -91.03% of loss for the given period.
Volatility was left at 6.32%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares surge +12.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.29% lower at present.
During the last 5 trading sessions, NLSP fell by -1.23%, which changed the moving average for the period of 200-days by -80.63% in comparison to the 20-day moving average, which settled at $1.5957. In addition, NLS Pharmaceutics Ltd saw -21.80% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for NLSP
The total capital return value is set at 0.32.
Based on NLS Pharmaceutics Ltd (NLSP), the company’s capital structure generated -0.23 points at debt to capital in total, while cash flow to debt ratio is standing at -0.89. The debt to equity ratio resting at -0.18. The interest coverage ratio of the stock is -14.19.
Currently, EBITDA for the company is -11.8 million with net debt to EBITDA at -0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.69.
Conclusion
In summary, NLS Pharmaceutics Ltd (NLSP) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
